Latest Astellas Pharma Inc. Stories
SAN MATEO, Calif., Aug. 9, 2011 /PRNewswire/ -- Recent Highlights: Completed equity and debt financing totaling $40 million QutenzaÂ® (capsaicin) 8% patch launch in U.S. building momentum in large U.S.
LONDON, June 13, 2011 /PRNewswire/ -- Ambit Biosciences Corporation and Astellas Pharma Inc. announced today results from a planned interim analysis in an ongoing Phase 2 study evaluating AC220, a potent and selective FLT3 inhibitor.
SAN DIEGO and TOKYO, June 9, 2011 /PRNewswire-FirstCall/ -- Ambit Biosciences Corporation and Astellas Pharma Inc.
DEERFIELD, Ill., June 6, 2011 /PRNewswire/ -- Astellas Pharma Global Development, Inc., a subsidiary of Astellas Pharma Inc.
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.